AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19080647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (40-45 Gy, 5 times a week)
Number of subjects: 83
Study 19080647 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control Group II)
Number of subjects: 83
Study 19080647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for resectable patients)
Number of subjects: 83
Study 19080647 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control Group II for resectable patients)
Number of subjects: 83
Study 19080647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for un-resectable patients)
Number of subjects: 83
Study 19080647 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control Group II for un-resectable patients)
Number of subjects: 83
Study 20043468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily
Number of subjects: 231
Study 20043468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 30 mg daily
Number of subjects: 231
Study 20043468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 20043468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (any dose)
Number of subjects: 231
Study 20043468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (extension study)
Number of subjects: 231
Study 14760040 — intervention group
Group type: COMPARATOR
Intervention: Health screening and health discussions in general practice (not quantified in the abstract)
Number of subjects: 18
Study 11327054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 48
Study 11327054 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 48
Study 11327054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 48
Study 11327054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 48
Study 9158975 — intervention group
Group type: EXPERIMENTAL
Intervention: McMaster Teen Program
Number of subjects: 21
Study 9158975 — intervention group
Group type: COMPARATOR
Intervention: Conventional didactic sex education program
Number of subjects: 21
Study 8108576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg a day for 3 consecutive days)
Number of subjects: 14
Study 8108576 — intervention group
Group type: COMPARATOR
Intervention: Clodronate (300 mg a day for 3 consecutive days)
Number of subjects: 14
Study 3501156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 154
Study 3501156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 31201036 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator attachments
Number of subjects: 50
Study 31201036 — intervention group
Group type: EXPERIMENTAL
Intervention: Bars
Number of subjects: 50
Study 31491758 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin
Number of subjects: 96
Study 31491758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29224823 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 92
Study 29224823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 mg/m2)
Number of subjects: 92
Study 26315857 — intervention group
Group type: EXPERIMENTAL
Intervention: FamCope intervention (nurse-led family-coping-orientated palliative home care intervention)
Number of subjects: 0
Study 24337348 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of renal masses
Number of subjects: 137
Study 24337348 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of renal masses in patients with newly diagnosed renal cell carcinoma
Number of subjects: 137
Study 23166425 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/day nasal salmon calcitonin and a home exercise program
Number of subjects: 50
Study 23166425 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 50
Study 19541917 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RT)
Number of subjects: 127
Study 19541917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive comparison therapy (ICT)
Number of subjects: 127
Study 19541917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 127
Study 17503984 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (60 mg/day)
Number of subjects: 91
Study 17503984 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 300 mg/day)
Number of subjects: 91
Study 15072661 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise band-filling during 6 monthly ambulant visits
Number of subjects: 40
Study 15072661 — intervention group
Group type: COMPARATOR
Intervention: Bolus-filling 4 weeks postoperatively
Number of subjects: 40
Study 15072661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-filling
Number of subjects: 40
Study 11743529 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cryotherapy
Number of subjects: 70
Study 11743529 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 70
Study 9376095 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS prevention workshop (4 sessions of 3 hours each)
Number of subjects: 394
Study 9376095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 394
Study 7701278 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16
Study 7701278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3610509 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine mouthwash
Number of subjects: 0
Study 3610509 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 0
Study 29738877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) 2 g orally 2 h preoperatively and two doses of 1 g TXA postoperatively
Number of subjects: 117
Study 29738877 — intervention group
Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA) 3 g administered in the operating room
Number of subjects: 117
Study 29738877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA)
Number of subjects: 117
Study 29738877 — intervention group
Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 117
Study 29738877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral group
Number of subjects: 117
Study 29738877 — intervention group
Group type: COMPARATOR
Intervention: Topical group
Number of subjects: 117
Study 29738877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study 26890957 — intervention group
Group type: EXPERIMENTAL
Intervention: Beam-like rods (BR)
Number of subjects: 129
Study 26890957 — intervention group
Group type: COMPARATOR
Intervention: Circular rods (CR)
Number of subjects: 129
Study 25024234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention
Number of subjects: 118
Study 25024234 — intervention group
Group type: COMPARATOR
Intervention: Stretching-strengthening control
Number of subjects: 118
Study 22647314 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in manualized CBT
Number of subjects: 162
Study 22647314 — intervention group
Group type: COMPARATOR
Intervention: No specific training (Control)
Number of subjects: 162
Study 21246842 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of rHuEpo at Zusanli (ST 36) and Shenshu (BL 23), 3 times a week for 2 months.
Number of subjects: 38
Study 21246842 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of rHuEpo, 3 times a week for 2 months (Control group).
Number of subjects: 38
Study 18411016 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behaviors, psychological variables, and QOL assessment
Number of subjects: 97
Study 18411016 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and CD4 cell count
Number of subjects: 97
Study 18411016 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and depressive symptoms
Number of subjects: 97
Study 18411016 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, physical activity, and depressive symptoms
Number of subjects: 97
Study 18411016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles
Number of subjects: 97
Study 16106314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 40
Study 16106314 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available spacer
Number of subjects: 40
Study 16106314 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade non-valved spacer
Number of subjects: 40
Study 16106314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder inhaler
Number of subjects: 40
Study 16106314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12693586 — intervention group
Group type: EXPERIMENTAL
Intervention: Artecom (group A)
Number of subjects: 352
Study 12693586 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine (group B)
Number of subjects: 352
Study 10408542 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose transdermal 17beta-estradiol (four skin patches each releasing 0.1 mg of estradiol daily, replaced every 2 to 3 days)
Number of subjects: 8
Study 10408542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7579128 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.5 microgram kg‐1 min‐1 for 20 min) after pretreatment with placebo
Number of subjects: 20
Study 7579128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7579128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepyramine (histamine‐H1‐receptor antagonist) pretreatment
Number of subjects: 20
Study 2123881 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate and human menopausal gonadotrophin (CC/HMG)
Number of subjects: 41
Study 2123881 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG) alone
Number of subjects: 41
Study 7438381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1239
Study 31678062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 109
Study 31678062 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 109
Study 28097355 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 1023
Study 26027245 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (ET) 90 mg continuously every day
Number of subjects: 40
Study 26027245 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib (ET) 90 mg intermittently 1‐3 times weekly
Number of subjects: 40
Study 23345574 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of prophylactic antibiotics
Number of subjects: 168
Study 23345574 — intervention group
Group type: COMPARATOR
Intervention: Community managed exacerbations
Number of subjects: 168
Study 23345574 — intervention group
Group type: COMPARATOR
Intervention: Hospital managed exacerbations
Number of subjects: 168
Study 23345574 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exacerbation rate
Number of subjects: 168
Study 23345574 — intervention group
Group type: COMPARATOR
Intervention: Hospital-managed exacerbation
Number of subjects: 168
Study 23345574 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation rate in the first 2 years
Number of subjects: 168
Study 23345574 — intervention group
Group type: COMPARATOR
Intervention: Weight z scores at 5 years of age
Number of subjects: 168
Study 21199487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic testing with graduate prompt techniques
Number of subjects: 77
Study 21199487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dynamic testing)
Number of subjects: 77
Study 19726903 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health center smoking cessation counseling program using the transtheoretical model
Number of subjects: 115
Study 19726903 — intervention group
Group type: COMPARATOR
Intervention: Korean Ministry of Health & Welfare smoking cessation program
Number of subjects: 115
Study 17887990 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 microg
Number of subjects: 680
Study 17887990 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol DPI 160/4.5 microg
Number of subjects: 680
Study 17887990 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI 200 microg
Number of subjects: 680
Study 14871253 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (90 microg/kg i.v.) given 3 h after idraparinux (7.5 mg s.c.)
Number of subjects: 12
Study 14871253 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (90 microg/kg i.v.) given 1 week after idraparinux (7.5 mg s.c.)
Number of subjects: 12
Study 11528604 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary behavioral treatment
Number of subjects: 24
Study 11528604 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 24
Study 9806026 — intervention group
Group type: EXPERIMENTAL
Intervention: CIV IL-2
Number of subjects: 115
Study 7702020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (50 g) added to a standard (40-g oral) fat load
Number of subjects: 11
Study 2484836 — intervention group
Group type: EXPERIMENTAL
Intervention: Livingston's chemotherapy combined with isoprinosine
Number of subjects: 3
Study 2484836 — intervention group
Group type: EXPERIMENTAL
Intervention: Livingston's chemotherapy with shortened treatment cycle (8 days) and isoprinosine
Number of subjects: 3
Study 2484836 — intervention group
Group type: COMPARATOR
Intervention: Livingston's chemotherapy (control group)
Number of subjects: 3
Study 757241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal cannula
Number of subjects: 300
Study 757241 — intervention group
Group type: COMPARATOR
Intervention: Flexible plastic cannula
Number of subjects: 300
Study 757241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cannulas
Number of subjects: 300
Study 31394955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 178
Study 31394955 — intervention group
Group type: COMPARATOR
Intervention: Nasal prong
Number of subjects: 178
Study 29925182 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 F Tiger Ⅰ shaping technique
Number of subjects: 159
Study 29925182 — intervention group
Group type: COMPARATOR
Intervention: 6 F Judkins and Amplatz catheters
Number of subjects: 159
Study 27101815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 1mg (1mgQ4wk)
Number of subjects: 385
Study 27101815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 3mg (3mgQ4wk)
Number of subjects: 385
Study 27101815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 6mg loading dose followed by 3mg (6mgLD+3mgQ4wk)
Number of subjects: 385
Study 27101815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 10mg (10mgQ4wk)
Number of subjects: 385
Study 27101815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 24675714 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein/Low Glycemic Index (HP/LGI)
Number of subjects: 256
Study 24675714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein/Low Glycemic Index (LP/LGI)
Number of subjects: 256
Study 24675714 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 256
Study 24675714 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein/High Glycemic Index (HP/HGI)
Number of subjects: 256
Study 24675714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein/High Glycemic Index (LP/HGI)
Number of subjects: 256
Study 22169830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle course in combination with physical activity (intervention group)
Number of subjects: 99
Study 22169830 — intervention group
Group type: COMPARATOR
Intervention: Physical activity alone (control group)
Number of subjects: 99
Study 20798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with bevacizumab (leucovorin, 5-fluorouracil plus irinotecan)
Number of subjects: 222
Study 20798560 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (leucovorin, 5-fluorouracil plus irinotecan)
Number of subjects: 222
Study 20798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with bevacizumab
Number of subjects: 222
Study 20798560 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 222
Study 19177819 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy
Number of subjects: 201
Study 19177819 — intervention group
Group type: COMPARATOR
Intervention: Conventional carotid endarterectomy
Number of subjects: 201
Study 16213302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg, three times a day, 12 weeks)
Number of subjects: 34
Study 16213302 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg, 2 weeks)
Number of subjects: 34
Study 16213302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 34
Study 16213302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous ganciclovir
Number of subjects: 34
Study 16213302 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 34
Study 12769004 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10685331 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus oral estriol 4 mg/day for 4 months (add-back group; n = 6)
Number of subjects: 12
Study 10685331 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate depot alone at a dose of 3.75 mg s.c. every month for 6 months (non add-back group; n = 6)
Number of subjects: 12
Study 10685331 — intervention group
Group type: COMPARATOR
Intervention: Non add-back group
Number of subjects: 12
Study 10685331 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa plus oral estriol add-back therapy
Number of subjects: 12
Study 8763462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamisil (terbinafine) 250 mg/day
Number of subjects: 0
Study 8763462 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg/day
Number of subjects: 0
Study 1811337 — intervention group
Group type: COMPARATOR
Intervention: Fish diet (200 g/d of lean Australian fish flesh)
Number of subjects: 12
Study 1811337 — intervention group
Group type: COMPARATOR
Intervention: Fish + Oil diet (200 g/d of lean Australian fish flesh + 5 g/d fish oil)
Number of subjects: 12
Study 1811337 — intervention group
Group type: COMPARATOR
Intervention: Fish + Oil diet
Number of subjects: 12
Study 1811337 — intervention group
Group type: COMPARATOR
Intervention: Fish diet
Number of subjects: 12
Study 1811337 — intervention group
Group type: COMPARATOR
Intervention: Fish diet and Fish + Oil diet
Number of subjects: 12
Study 1811337 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study 6130658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.4 mg i.v.)
Number of subjects: 21
Study 6130658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (5 mg i.v.)
Number of subjects: 21
Study 6740566 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment (subcutaneous or intravenous)
Number of subjects: 98
Study 6740566 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin treatment
Number of subjects: 98
Study 6740566 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent thromboembolic episodes
Number of subjects: 98
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bbr alone
Number of subjects: 60
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fbt alone
Number of subjects: 60
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: Svt alone
Number of subjects: 60
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bbr plus Fbt
Number of subjects: 60
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bbr plus Svt
Number of subjects: 60
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 60
Study 30587933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of Bbr with Fbt and Svt
Number of subjects: 60
Study 29451825 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Object Relations Scale-Global Rating Method (SCORS-G)
Number of subjects: 0
Study 29451825 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 27251185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry beverage (240 mL/day)
Number of subjects: 373
Study 27251185 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 373
Study 24864125 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133
Study 24864125 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV followed by nonadjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133
Study 24864125 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133
Study 24864125 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline followed by nonadjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133
Study 22554673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 249
Study 22554673 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 249
Study 20190704 — intervention group
Group type: EXPERIMENTAL
Intervention: Method C (Integran, a sheet-type absorbable topical collagen hemostat)
Number of subjects: 72
Study 20190704 — intervention group
Group type: COMPARATOR
Intervention: Method G (combined approach with TachoComb or PGA sheet fixed with fibrin glue)
Number of subjects: 72
Study 17659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 15603
Study 17659194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603